Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial.

Jeff P. Sharman; Charles M. Farber; Daruka Mahadevan; Marshall T. Schreeder; Heather D. Brooks; Kathryn S. Kolibaba; Suzanne Fanning; Leonard Klein; Daniel R. Greenwald; Peter Sportelli; Hari P. Miskin; Michael S. Weiss; John M. Burke

doi:10.1111/BJH.14447

Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial.

Jeff P. Sharman
, Charles M. Farber
, Daruka Mahadevan
, Marshall T. Schreeder
, Heather D. Brooks
, Kathryn S. Kolibaba
, Suzanne Fanning
, Leonard Klein
, Daniel R. Greenwald
, Peter Sportelli
, Hari P. Miskin
, Michael S. Weiss
, John M. Burke

Willamette University
Carol G. Simon Cancer Center, Morristown, NJ, USA.
University of Tennessee Health Science Center
Clearview Cancer Institute, Huntsville, AL, USA.
US Oncology Research Morristown NJ USA
Greenville Health System
TG Therapeutics, Inc., New York, NY, USA.

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	British Journal of Haematology
Volume	176
Issue number	3
DOIs	https://doi.org/10.1111/BJH.14447
State	Published - Feb 1 2017
Externally published	Yes

Disciplines

Pharmacology
Medicine and Health Sciences
Oncology
Internal Medicine

Access to Document

10.1111/BJH.14447License: Unspecified

Cite this

Sharman, J. P., Farber, C. M., Mahadevan, D., Schreeder, M. T., Brooks, H. D., Kolibaba, K. S., Fanning, S., Klein, L., Greenwald, D. R., Sportelli, P., Miskin, H. P., Weiss, M. S., & Burke, J. M. (2017). Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial. British Journal of Haematology, 176(3). https://doi.org/10.1111/BJH.14447

Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial. / Sharman, Jeff P.; Farber, Charles M.; Mahadevan, Daruka et al.
In: British Journal of Haematology, Vol. 176, No. 3, 01.02.2017.

Research output: Contribution to journal › Article › peer-review

Sharman, JP, Farber, CM, Mahadevan, D, Schreeder, MT, Brooks, HD, Kolibaba, KS, Fanning, S, Klein, L, Greenwald, DR, Sportelli, P, Miskin, HP, Weiss, MS & Burke, JM 2017, 'Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial.', British Journal of Haematology, vol. 176, no. 3. https://doi.org/10.1111/BJH.14447

Sharman JP, Farber CM, Mahadevan D, Schreeder MT, Brooks HD, Kolibaba KS et al. Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial. British Journal of Haematology. 2017 Feb 1;176(3). doi: 10.1111/BJH.14447

@article{d6dbbdc0104044ca98f89b3a66f6e971,

title = "Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial.",

author = "Sharman, \{Jeff P.\} and Farber, \{Charles M.\} and Daruka Mahadevan and Schreeder, \{Marshall T.\} and Brooks, \{Heather D.\} and Kolibaba, \{Kathryn S.\} and Suzanne Fanning and Leonard Klein and Greenwald, \{Daniel R.\} and Peter Sportelli and Miskin, \{Hari P.\} and Weiss, \{Michael S.\} and Burke, \{John M.\}",

note = "The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.",

year = "2017",

month = feb,

day = "1",

doi = "10.1111/BJH.14447",

language = "American English",

volume = "176",

journal = "British Journal of Haematology",

number = "3",

}

TY - JOUR

T1 - Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial.

AU - Sharman, Jeff P.

AU - Farber, Charles M.

AU - Mahadevan, Daruka

AU - Schreeder, Marshall T.

AU - Brooks, Heather D.

AU - Kolibaba, Kathryn S.

AU - Fanning, Suzanne

AU - Klein, Leonard

AU - Greenwald, Daniel R.

AU - Sportelli, Peter

AU - Miskin, Hari P.

AU - Weiss, Michael S.

AU - Burke, John M.

N1 - The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.

PY - 2017/2/1

Y1 - 2017/2/1

UR - https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.14447

U2 - 10.1111/BJH.14447

DO - 10.1111/BJH.14447

M3 - Article

VL - 176

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 3

ER -

Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial.

Disciplines

Access to Document

Other files and links

Cite this